Personalis, Inc.
(NASDAQ : PSNL)

( )
PSNL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.99%59.150.0%$907.20m
AMGNAmgen, Inc. -0.77%256.251.3%$749.53m
GILDGilead Sciences, Inc. 0.54%76.761.0%$694.38m
REGNRegeneron Pharmaceuticals, Inc. 0.77%627.252.5%$662.27m
BIIBBiogen, Inc. 1.77%269.801.6%$578.06m
NVAXNovavax, Inc. -2.70%79.44102.0%$554.12m
VRTXVertex Pharmaceuticals, Inc. 0.07%291.311.9%$511.41m
ILMNIllumina, Inc. 1.69%379.393.5%$304.71m
ALXNAlexion Pharmaceuticals, Inc. 1.13%113.572.0%$235.48m
BMRNBioMarin Pharmaceutical, Inc. 0.73%127.714.3%$217.46m
SGENSeattle Genetics, Inc. 0.84%170.456.1%$198.74m
SRNESorrento Therapeutics, Inc. 4.60%7.171.8%$192.02m
IMMUImmunomedics, Inc. 8.23%40.6311.0%$178.71m
SRPTSarepta Therapeutics, Inc. 0.46%163.4913.9%$171.15m
INCYIncyte Corp. 1.24%107.792.5%$164.33m

Company Profile

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.